| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 296 |
| 1 | ATEZOLIZUMAB | 228 |
| 2 | FUROSEMIDE | 199 |
| 3 | SPIRONOLACTONE | 194 |
| 4 | RIBAVIRIN | 158 |
| 5 | PROPRANOLOL HYDROCHLORIDE | 113 |
| 6 | SOFOSBUVIR | 108 |
| 7 | OMEPRAZOLE MAGNESIUM | 98 |
| 8 | LENVATINIB | 97 |
| 9 | LACTULOSE | 83 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ETHANOLAMINE OLEATE | 5 | 0.2778 |
| 1 | TERLIPRESSIN | 4 | 0.0121 |
| 2 | ATEZOLIZUMAB | 228 | 0.0057 |
| 3 | SOFOSBUVIR | 108 | 0.0055 |
| 4 | ZIV-AFLIBERCEPT | 7 | 0.0054 |
| 5 | NADOLOL | 34 | 0.0045 |
| 6 | SORAFENIB | 82 | 0.0040 |
| 7 | ADEFOVIR DIPIVOXIL | 5 | 0.0039 |
| 8 | NELFINAVIR MESYLATE | 8 | 0.0038 |
| 9 | NIZATIDINE | 5 | 0.0033 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vasopressin Receptor Agonist [EPC] | 4 | 0.0121 |
| 1 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 182 | 0.0035 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 248 | 0.0025 |
| 3 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 15 | 0.0024 |
| 4 | Peroxisome Proliferator-activated Receptor Agonist [EPC] | 2 | 0.0022 |
| 5 | Vasopressin V2 Receptor Antagonist [EPC] | 30 | 0.0020 |
| 6 | Nucleoside Analog Antiviral [EPC] | 167 | 0.0020 |
| 7 | Hepatitis C Virus NS5A Inhibitor [EPC] | 86 | 0.0018 |
| 8 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 86 | 0.0017 |
| 9 | Bile Acid [EPC] | 40 | 0.0017 |